Ertugliflozin: Phase III data

The double-blind, international Phase III VERTIS Mono trial in 461 Type II diabetics inadequately controlled on diet and exercise showed that once-daily 5 and 15 mg ertugliflozin each met the primary endpoint

Read the full 320 word article

How to gain access

Continue reading with a
two-week free trial.